Back to Search
ROBERT A MAIRS DO
DO
Obstetrics & Gynecology Physician
NPI: 1124001862IndividualAccepts Medicare
Specialties, Licenses & Credentials
Gynecology Physician
Obstetrics & Gynecology — Gynecology
Code: 207VG0400X
O-186(ID)DO20644(OR)
Obstetrics & Gynecology PhysicianPrimary
Obstetrics & Gynecology
Code: 207V00000X
DO20644(OR)
Education
AT STILL UNIVERSITY OF HEALTH SCIENCES, COLLEGE OF OSTEO MED, KIRKSVILLE
Class of 1993
Research & Publications (20)
Microsatellite analysis for determination of the mutagenicity of extremely low-frequency electromagnetic fields and ionising radiation in vitro.
PMID 16987695·Mutat Res·2007
8-other
A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
PMID 17704246·J Nucl Med·2007
7-preclinical
Targeted radiotherapy: microgray doses and the bystander effect.
PMID 18648605·Dose Response·2007
8-other
National symposium on low-dose radiation and bystander effects -12 October 2004, Cancer Research UK Beatson Laboratories, Glasgow. Sponsored by Glasgow University School for Cancer Studies, the Department of Health and the National Cancer Research Institute.
PMID 16019935·Int J Radiat Biol·2005
7-preclinical
Gene manipulation to enhance MIBG-targeted radionuclide therapy.
PMID 16243651·Nucl Med Biol·2005
6-review
Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model.
PMID 10638969·Br J Cancer·2000
4-observational
Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
PMID 18819996·Br J Radiol·2008
7-preclinical
Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
PMID 18707637·Nucl Med Biol·2008
6-review
Radiation quality-dependent bystander effects elicited by targeted radionuclides.
PMID 18644188·J Pharm Pharmacol·2008
6-review
p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.
PMID 17006546·Gene Ther·2007
7-preclinical
Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
PMID 16741311·J Nucl Med·2006
8-other
Radioprotective gene therapy through retroviral expression of manganese superoxide dismutase.
PMID 16506247·J Gene Med·2006
7-preclinical
[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
PMID 15935554·Cancer Lett·2005
6-review
Application of targeted radiotherapy/gene therapy to bladder cancer cell lines.
PMID 15661422·Eur Urol·2005
8-other
Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
PMID 15869455·Cancer Biother Radiopharm·2005
8-other
[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
PMID 16278418·Clin Cancer Res·2005
7-preclinical
Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
PMID 16787326·Med Chem·2005
4-observational
Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
PMID 16787344·Med Chem·2005
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 9850 W ST LUKES DR STE 320A
NAMPA, ID 83687 - Phone
- (208) 706-3220
Quick Facts
- NPI
- 1124001862
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 3
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile